Tags » Cetuximab

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study

PURPOSE: RAS mutations predict lack of response to epidermal growth factor receptor monoclonal antibody therapy in patients with metastatic colorectal cancer (mCRC), but preclinical studies and retrospective clinical data suggest that patients with tumors harboring the exon 2 KRAS G13D mutation may benefit from cetuximab. 255 more words


Delivering the Goods: Enhancing Cancer Therapeutic Uptake in Solid Tumors

By Jennifer Souratha

Cancer treatments aim to attack rogue cells that cause chaos in the body. An anticancer agent’s main objective is to reach the target cells and, in a therapeutic window, defeat them without damaging the rest of the body. 361 more words

AAPS Events

Inovasi terbaru imunoterapi untuk pasien kanker kolorektal

Harapan hidup pasien kanker kolorektal bergerak dari 1 tahun di tahun 2000-an menuju hampir 3 tahun di tahun 2014. Kemajuan ilmu genetik kanker kini memungkinkan untuk memprediksi, mendeteksi dan mengobati kanker secara tepat dan efektif. 141 more words

For Public